AbCellera Results Presentation Deck
DAY 0
Sample
received
THE 1ST COVID-19 ANTIBODY TREATMENT
TO REACH THE CLINIC IN N. AMERICA.
from one of the
first US patients
who recovered
from COVID-19.
2020 BUSINESS UPDATE. COVID-19 PROGRAM
Together with its partners, AbCellera brought the first treatment developed specifically for COVID-19.
Bamlanivimab is currently authorized in 15 countries, including the United States, Canada, Europe
and the Middle East for the treatment of mild to moderate COVID-19 in high-risk patients.
86
From patient sample to human testing in 90 days
~5,800,000 cells
screened in 3 days
24 leads identified
in 23 days by evaluating
250,000 data points
DA
DAY 90
Y
‒‒
Ab Cellera
one antibody
in human clinical testing
by Eli Lilly and Company
COPYRIGHT ABCELLERA
9View entire presentation